Shares of Cardiome Pharma Corp. got a nice boost Monday after the company reported promising interim results from a Phase IIb study showing that its arrhythmia drug oral vernakalant significantly increased the median time to relapse compared to placebo. (BioWorld Today)
Shares of Tarrytown, N.Y.-based Progenics Pharmaceuticals Inc. lost more than half their value after the company, along with partner Wyeth Pharmaceuticals, reported disappointing Phase III data of methylnaltrexone (MNTX) in postoperative ileus, casting a dark cloud of investor worry over the expansive MNTX program, which includes a pending new drug application for opioid-induced constipation. (BioWorld Today)
